Zydus Launches IBYRA, the Generic Version of Olaparib, Brings Both Access and Affordability for Cancer Patients in India
Mar 14, 2024
Ahmedabad (Gujarat) [India], March 14: In a significant stride towards making advanced cancer treatment accessible to all, Zydus has launched Olaparib, a PARP inhibitor, under the brand name IBYRA in India. The drug will target specific genetic mutations prevalent in certain types of cancers, paving the way for more tailored and effective treatment approach.
Read More...
